{"id":"NCT01909453","sponsor":"Pfizer","briefTitle":"Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma","officialTitle":"A 2-part Phase III Randomized, Open Label, Multicenter Study of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-09-12","primaryCompletion":"2016-11-09","completion":"2024-09-03","firstPosted":"2013-07-26","resultsPosted":"2021-07-12","lastUpdate":"2025-05-29"},"enrollment":921,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Melanoma"],"interventions":[{"type":"DRUG","name":"LGX818","otherNames":[]},{"type":"DRUG","name":"MEK162","otherNames":[]},{"type":"DRUG","name":"vemurafenib","otherNames":["Zelboraf","PLX4032","RO5185426"]}],"arms":[{"label":"LGX818 450 mg + MEK162","type":"EXPERIMENTAL"},{"label":"Vemurafenib","type":"ACTIVE_COMPARATOR"},{"label":"LGX818 300 mg + MEK162","type":"EXPERIMENTAL"},{"label":"LGX818","type":"EXPERIMENTAL"}],"summary":"This is 2-part, randomized, open label, multi-center, parallel group, phase III study comparing the efficacy and safety of LGX818 plus MEK162 to vemurafenib and LGX818 monotherapy in patients with locally advanced unresectable or metastatic melanoma with BRAF V600 mutation. A total of approximately 900 patients will be randomized.\n\nPart 1:\n\nPatients will be randomized in a 1:1:1 ratio to one of 3 treatment arms:\n\n1. LGX818 450 mg QD plus MEK162 45 mg BID (denoted as Combo 450 arm)\n2. LGX818 300 mg QD monotherapy (denoted as LGX818 arm) or\n3. vemurafenib 960 mg BID (denoted as vemurafenib arm)\n\nPart 2:\n\nPatients will be randomized in a 3:1 ratio to one of the 2 treatment arms:\n\n1. LGX818 300 mg QD plus MEK162 45 mg BID (denoted as Combo 300 arm) or\n2. LGX818 300 mg QD monotherapy (denoted as LGX818 arm)","primaryOutcome":{"measure":"Part 1: Progression Free Survival (PFS) by Blinded Independent Review Committee (BIRC) in Combo 450 Group as Compared to Vemurafenib Group","timeFrame":"From randomization until documented disease progression (PD), initiation of new anti-cancer therapy, censoring date or death, whichever occurred first (up to 29 months)","effectByArm":[{"arm":"Part 1:LGX818 450 mg QD+MEK162 45 mg BID (Combo 450)","deltaMin":14.9,"sd":null},{"arm":"Part 1: Vemurafenib 960 mg BID","deltaMin":7.3,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":14},"locations":{"siteCount":282,"countries":["United States","Argentina","Australia","Brazil","Canada","Colombia","Czechia","France","Germany","Greece","Hungary","Israel","Italy","Japan","Mexico","Netherlands","Norway","Poland","Portugal","Russia","Singapore","Slovakia","South Africa","South Korea","Spain","Sweden","Switzerland","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":["37534686","37506329","37309702","36653848","35862871","34091420","31437754","30219628","29573941"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":66,"n":192},"commonTop":["Arthralgia","Nausea","Alopecia","Fatigue","Diarrhoea"]}}